Skip to main content
main-content
Top

17-06-2010 | Diabetes | Article

Exenatide treatment could be useful for weight loss in nondiabetic obese

Abstract

Free abstract

MedWire News: Exenatide treatment plus lifestyle modification is effective for promoting weight loss and improving glucose tolerance in nondiabetic and prediabetic obese individuals, show study results.

Exenatide plus lifestyle modification has previously been shown to improve glycemic control and reduce weight in Type 2 diabetes patients when taken in combination with metformin or a sulfonylurea, as reported by MedWire News.

In this study, Julio Rosenstock (Dallas Diabetes and Endocrine Center at Medical City, Texas, USA) and colleagues assessed the efficacy of exenatide for improving weight and glucose tolerance in 152 nondiabetic obese individuals, of whom 25% had impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). The participants had an average body mass index of 39.6 kg/m2 and weight of 108.6 kg and were aged 46 years on average.

They were randomly assigned to receive exenatide 5–10 µg (n=73) or placebo (n=79) twice daily before morning and evening meals for a period of 24 weeks. During this period a structured diet and exercise program was also implemented.

Writing in the journal Diabetes Care, the team reports that from baseline, patients in the exenatide-treated group lost 5.1 kg in body weight compared with a reduction of only 1.6 kg in the placebo group, amounting to a significant 3.3 kg difference .

In addition, by the end of the study 77% of exenatide-treated and 56% of placebo-treated individuals had normalized IGT or IFG.

The team notes that no deaths, serious adverse events, or hypoglycemia were observed during the study. Nausea and diarrhea were more common in the exenatide-treated patients than the placebo group, at 25% and 14% versus 4% and 3%, respectively.

“The current findings warrant further studies to explore the potential role of glucagon-like peptide-1 receptor agonists for the treatment of obese subjects with IGT or IFG,” conclude the authors.

They suggest: “Exenatide, in addition to lifestyle modification, has potential as a treatment for obesity in subjects at high risk for developing Type 2 diabetes.”

MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010

By Helen Albert

Literature